Who is referred to neurology clinics?—The diagnoses made in 3781 new patients

Stone, Jon; Carson, Alan; Duncan, Roderick; Roberts, Richard C.; Warlow, Charles; Hibberd, Carina; Coleman, R. J.; Cull, R. E.; Murray, Gordon D.; Pelosi, Anthony J.; Cavanagh, Jonathan; Matthews, Keith; Goldbeck, Rainer; Smyth, Roger; Walker, Jane; Sharpe, Michael

doi:10.1016/j.clineuro.2010.05.011

Cited by 425 publications

(320 citation statements)

References 13 publications

Supporting

Mentioning

297

Contrasting

Unclassified

Order By: Relevance

“…Both PNES and PMD are commonly seen in clinical practice (up to 20% of outpatients 1,2 ), but their precise prevalence and incidence are unknown. The only population-based study available yielded an incidence of PNES of 1.4 per 100,000, with highest age-specific incidence (3.4 per 100,000) in the 15-24 years age group.…”

Section: Epidemiology and Demographicsmentioning

confidence: 99%

Psychogenic nonepileptic seizures and movement disorders

et al. 2016

View full text Add to dashboard Cite

Purpose of review: Neurologic symptoms due to a psychogenic cause are frequently seen in clinical practice. Psychogenic nonepileptic seizures (PNES) and psychogenic movement disorders (PMD) are among the most common psychogenic neurologic disorders. PNES and PMD are usually investigated and managed separately by different neurology subspecialists. We review the main epidemiologic and clinical features of both PNES and PMD, aiming to highlight their similarities and differences and to see whether a common framework for these disorders exists. Recent findings:Data from the literature show that there is a profound overlap between PNES and PMD, which would argue for a larger unifying pathophysiology with variable phenotypic manifestations. Summary: Collaborative and integrated research among epileptologists, movement disorders experts, psychiatrists, psychologists, and physiotherapists may increase our collective knowledge about the pathophysiologic mechanisms of PNES and PMD and therefore improve outcomes for these patients. Neurol Clin Pract 2016;6:138-149 N eurologic symptoms due to a functional or psychogenic cause are common in clinical practice, accounting for up to 16% of patients presenting to neurology outpatient clinics, depending on the clinical definitions and methodology used for case ascertainment.1,2 The yearly costs of patients with medically unexplained symptoms in the United States have been estimated at approximately $256 billion per year.3 Despite their prevalence and associated economic and social burden, appropriate treatments for these disorders are an unmet need. This may reflect the absence of research interest and lack of discourse between neurology and psychiatry regarding these patients. Notably, although approximately 50% of the patients with somatoform disorders are identified by neurologists at the time of first contact, only 1.5% are referred to a psychiatrist or a psychologist.

show abstract

Section: Epidemiology and Demographicsmentioning

confidence: 99%

Psychogenic nonepileptic seizures and movement disorders

et al. 2016

View full text Add to dashboard Cite

show abstract

“…1 Patients affected by FMS have levels of disability, distress and healthcare usage that equals, and in some cases surpasses, patients with neurodegenerative disease. 2 Recent years have seen a surge of research interest in functional neurological symptoms.…”

Section: Introductionmentioning

confidence: 99%

The Role of Alexithymia in the Development of Functional Motor Symptoms (Conversion Disorder)

Demartini

Petrochilos

Ricciardi

et al. 2014

Journal of Neurology, Neurosurgery & Psychiatry

View full text Add to dashboard Cite

“…Headache accounts for 4.4% of all consultations in general practice [Tepper et al 2004;Kernick et al 2008b], approximately 5% of all medical admissions to hospital [Weatherall, 2006], and approximately 20% of neurology outpatient consultations [Stone et al 2010]. Migraine affects over 20% of people at some point in their lives; epidemiological studies have shown that 4.5% of the population of Western Europe has headache on at least 15 days per month [Welch and Goadsby, 2002]; global studies suggest that approximately 1% of the world's population may have chronic migraine [Natoli et al 2010].…”

Section: Introductionmentioning

confidence: 99%

The diagnosis and treatment of chronic migraine

Weatherall

2015

Therapeutic Advances in Chronic Disease

146

View full text Add to dashboard Cite

Abstract:Migraine is the most common disabling brain disorder. Chronic migraine, a condition characterized by the experience of migrainous headache on at least 15 days per month, is highly disabling. Patients with chronic migraine present to primary care, are often referred for management to secondary care, and make up a large proportion of patients in specialist headache clinics. Many patients with chronic migraine also have medication overuse, defined as using a compound analgesic, opioid, triptan or ergot derivative on at least 10 days per month. All doctors will encounter patients with chronic headaches. A basic working knowledge of the common primary headaches, and a rational manner of approaching the patient with these conditions, allows a specific diagnosis of chronic migraine to be made quickly and safely, and by making this diagnosis one opens up a substantial number of acute and preventive treatment options. This article discusses the current state of management of chronic migraine.

show abstract

Who is referred to neurology clinics?—The diagnoses made in 3781 new patients

Cited by 425 publications

References 13 publications

Psychogenic nonepileptic seizures and movement disorders

Psychogenic nonepileptic seizures and movement disorders

The Role of Alexithymia in the Development of Functional Motor Symptoms (Conversion Disorder)

The diagnosis and treatment of chronic migraine

Contact Info

Product

Resources

About